InxMed (Shanghai) Co. has dosed the first patient in a Phase Ib trial of its focal adhesion kinase (FAK) inhibitor in melanoma patients. The trial will conducted in Australia and the US in patients with metastatic uveal melanoma or NRAS mutant metastatic melanoma. IN10018 will be tested as a monotherapy and in combination with Roche's MEK inhibitor Cotellic (cobimetinib), which was approved to treat melanoma in 2015. Previously, InxMed was approved to start a China Phase I trial of IN10018 in patients with advanced or metastatic gastric cancer.
seekingalpha.com/article/43...
missy
Our 26 yr old son just back from Marines dx Melanoma Stage 3. We need to understand the next step. 
